To predict the magnitude of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier (BBB), rodent studies are routinely conducted where P-gp is chemically inhibited. For such studies to be predictive of interactions at the human BBB, the plasma concentration of the P-gp inhibitor must be comparable with that observed in the clinic. Therefore, we determined the in vivo EC50 of P-gp inhibition at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to ∼12 μM. Then, an i.v. tracer dose of [3H]verapamil was administered, and 20 min after verapamil administration, the animals were sacrificed for determination of blood, plasma, and brain 3H radioactivity by scintillation counting. The percentage increase in the brain/blood 3H radioactivity (relative to 0 μM CsA) was described by the Hill equation with Emax, 1290%; EC50, 7.2 μM; and γ, 3.8. Previously, using [11C]verapamil, we have shown that the human brain/blood 11C radioactivity was increased by 79% at 2.8 μM CsA blood concentration. At an equivalent CsA blood concentration, the rat brain/blood 3H radioactivity was increased by a remarkably similar extent of 75%. This is the first time that an in vivo CsA EC50 of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Pharmacology and Experimental Therapeutics|
|State||Published - May 2006|
ASJC Scopus subject areas
- Molecular Medicine